Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

751
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
751
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.9K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.9K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.7K
The pathophysiology of pneumonia involves the following steps:
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geographical, institutional and workplace variability in genetic evaluation, screening practices, multidisciplinary care, and lung transplantation management for familial interstitial lung disease.

BMC pulmonary medicine·2026
Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026
Same author

Real-World Experience with Nintedanib in a Progressive Pulmonary Fibrosis Cohort.

Medicina (Kaunas, Lithuania)·2026
Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026
Same author

A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.

Pulmonary circulation·2026
Same author

[2027: A new year for a new epidemiological study of chronic obstructive pulmonary disease in Spain].

Open respiratory archives·2026

Related Experiment Video

Updated: Mar 9, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K

Idiopathic pulmonary fibrosis.

Antoni Xaubet1, Julio Ancochea2, María Molina-Molina3

  • 1Servicio de Neumología, Hospital Clínic, Barcelona, España.

Medicina Clinica
|December 22, 2016
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unknown causes. Diagnosis relies on imaging and biopsy, with anti-fibrotic drugs or lung transplant as primary treatments.

Keywords:
Fibrosis pulmonar idiopáticaIdiopathic pulmonary fibrosisInterstitial pneumoniaNeumonía intersticialTratamientoTreatment

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.2K

Related Experiment Videos

Last Updated: Mar 9, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.2K

Area of Science:

  • Pulmonology
  • Fibrotic Interstitial Pneumonia
  • Usual Interstitial Pneumonia (UIP) pattern

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial pneumonia.
  • The etiology of IPF is unknown, likely involving genetic predisposition and environmental factors.
  • IPF is characterized by the radiological and/or histological pattern of usual interstitial pneumonia (UIP).

Purpose of the Study:

  • To review the diagnostic criteria for idiopathic pulmonary fibrosis.
  • To outline the therapeutic strategies for idiopathic pulmonary fibrosis.
  • To discuss complications and comorbidities impacting IPF prognosis.

Main Methods:

  • Diagnosis is based on high-resolution computed tomography (HRCT) scans and pulmonary biopsies.
  • Exclusion of other interstitial lung diseases is crucial for IPF diagnosis.
  • Clinical course and prognosis are influenced by disease severity, complications, and comorbidities.

Main Results:

  • The mean survival rate for IPF is 2-5 years from clinical presentation.
  • Mild-moderate IPF is treated with anti-fibrotic drugs.
  • Severe IPF cases are candidates for lung transplantation.

Conclusions:

  • Accurate diagnosis of IPF requires characteristic HRCT and biopsy findings, excluding other causes.
  • Treatment strategies for IPF are stratified by disease severity.
  • Management of IPF involves addressing complications and comorbidities to improve patient outcomes.